RBC Capital Maintains Outperform on Amgen, Raises Price Target to $430

Benzinga Newsdesk www.benzinga.com Positive 90.5%

Neg 0% Neu 0% Pos 90.5%

RBC Capital analyst Luca Issi maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $400 to $430.